Sarcopenia, a condition characterized by age - related muscle loss and strength decline, is a growing health concern.

Beyond the drugs targeting specific pathways like the Activin - ActRII - ActRI pathway, there are other medications being developed for obesity and muscle - wasting disorders.

The discovery of INHBE and ALK7 as potential drug targets has opened up new avenues in the development of therapies for obesity and metabolic disorders.

By conducting in - depth searches in relevant databases, the development of drugs targeting MSTN/GDF8 and bone morphogenetic proteins (BMPs) has been revealed.

Through comprehensive searches in the Patsnap Synapse database, it has been found that the key drugs targeting ActRII mainly consist of fusion proteins and monoclonal antibodies.

In the pursuit of treating muscle - related diseases and achieving effective weight management with the goal of “fat loss with muscle gain”.

The Activin - ActRII - ActRI pathway plays a vital role in cell growth and differentiation, and understanding its mechanism of action is essential.

The Activin - ActRII - ActRI pathway is a key regulatory pathway in muscle growth and has attracted significant attention in the research of muscle - related diseases and weight - loss therapies.

With the widespread use of Semaglutide in weight management, the issue of weight rebound after discontinuation has emerged as a significant challenge.

Semaglutide has been increasingly utilized for chronic weight management in obese or overweight adults due to its remarkable weight - loss effects.

This report outlines the process of monoclonal antibody drug patent research with the investigation of BeiGene patent portfolio related to its tislelizumab monoclonal antibody.

Tislelizumab, referred to as bazeleus, represents a humanized IgG4 monoclonal antibody targeting PD-1.